<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183895</url>
  </required_header>
  <id_info>
    <org_study_id>4631</org_study_id>
    <nct_id>NCT03183895</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Performance of the AccuCinch® Ventricular Repair System</brief_title>
  <official_title>Safety and Performance Evaluation of the AccuCinch® Ventricular Repair System for Functional Mitral Regurgitation Due to Dilated Ischemic or Non-Ischemic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ancora Heart, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ancora Heart, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international multi-center, non-randomized, prospective safety and performance
      study to AccuCinch® Ventricular Repair System in patients with Functional Mitral
      Regurgitation Due to Dilated Ischemic or Non-Ischemic Cardiomyopathy
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2019</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety outcome: 30-day major adverse events (MAEs)</measure>
    <time_frame>30-day</time_frame>
    <description>Major adverse event (MAE) where MAE is a composite of the following device- or procedure-related events:
A. All-cause mortality
B. Stroke
C. Life-threatening bleeding (MVARC scale)
D. Major vascular complications
E. Major cardiac structural complications
F. Myocardial infarction or coronary ischemia requiring PCI or CABG
G. Stage 2 or 3 acute kidney injury (includes new dialysis)
H. Severe hypotension, worsening of heart failure, or respiratory failure requiring intravenous pressors or invasive or mechanical heart failure treatments such as ultrafiltration or hemodynamic assist devices, including intra-aortic balloon pumps or left ventricular or biventricular assist devices, or prolonged intubation for &gt;48 h.
I. Emergency surgery or re-intervention related to the device or access procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success: Successful access, delivery, and retrieval of AccuCinch System components, successful deployment of the AccuCinch implant without need for unplanned or emergency surgery or re-intervention</measure>
    <time_frame>30-day</time_frame>
    <description>Successful access, delivery, and retrieval of all AccuCinch catheters. Deployment and correct positioning of the intended AccuCinch implant, and no need for additional unplanned or emergency surgery or re-intervention related to the device or access procedure measured upon completion of the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional performance: Reduction in regurgitant volume when compared to baseline</measure>
    <time_frame>30-day</time_frame>
    <description>Reduction in regurgitant volume (RVol) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional performance: Reduction in effective regurgitant orifice area when compared to baseline</measure>
    <time_frame>30-day</time_frame>
    <description>Reduction in effective regurgitant orifice area (EROA) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural performance: Assessment of device integrity</measure>
    <time_frame>30-day</time_frame>
    <description>No migration, embolization, detachment, fracture, hemolysis, thrombosis or endocarditis; and no para-device complications (erosion, effusion requiring surgery or drainage or producing tamponade, damage to the MV apparatus)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome: Freedom from re-hospitalizations or re-interventions for the underlying condition</measure>
    <time_frame>30-day</time_frame>
    <description>Freedom from re-hospitalizations or re-interventions for the underlying condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome: Improvement in NYHA functional class</measure>
    <time_frame>30-day</time_frame>
    <description>Improvement in NYHA functional class when compared to baseline assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome: Improvement in six-minute walk test</measure>
    <time_frame>30-day</time_frame>
    <description>Improvement in six-minute walk test (6MWT) when compared to baseline assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome: Improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) Quality of Life (QoL)</measure>
    <time_frame>30-day</time_frame>
    <description>Improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) Quality of Life (QoL) when compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Heart Failure</condition>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>AccuCinch® Ventricular Repair System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitral valve repair</intervention_name>
    <description>The AccuCinch® Ventricular Repair System, implanted in the sub-valvular space of the left ventricle, is intended to reduce significant symptomatic mitral regurgitation and reverse left ventricular remodeling due to dilated cardiomyopathy of either ischemic or non-ischemic etiology via percutaneous interventional methods.</description>
    <arm_group_label>AccuCinch® Ventricular Repair System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 yrs

          -  Severity of FMR: ≥ Moderate 2+

          -  LVEF &gt;20% to&lt;60%

          -  Symptom Status: NYHA II-Iva

          -  Functional mitral regurgitation due to dilated cardiomyopathy of ischemic or
             non-ischemic etiology

          -  Treatment and compliance with optimal guideline-directed medical therapy for heart
             failure for at least 30 days

          -  Surgical risk: Subject is eligible for cardiac surgery (specific risk score or
             comorbidities should demonstrate high risk features, as determined by the Heart Team)
             High risk for mitral valve surgery is defined utilizing established risk scores (STS,
             Euro-Score II) in conjunction with comorbidities as recommended by MVARC (frailty
             index; major organ system compromise not to be improved postoperatively; procedure
             specific impediments) (MVARC Part 1)

          -  Completion of all qualifying diagnostic and functional tests and agrees to comply with
             study follow-up schedule

        Exclusion Criteria:

          -  Life expectancy &lt;1 yr due to noncardiac conditions

          -  NYHA functional class IVb or ACC/AHA stage D heart failure

          -  Hypotension (systolic pressure &lt;90 mm Hg) or requirement for inotropic support or
             mechanical hemodynamic support

          -  UNOS status 1 heart transplantation or prior orthotopic heart transplantation

          -  Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or
             any other structural heart disease causing heart failure other than dilated
             cardiomyopathy of either ischemic or nonischemic etiology

          -  Fixed pulmonary artery systolic pressure &gt;70 mm Hg

          -  Physical evidence of right-sided congestive heart failure with echocardiographic
             evidence of moderate or severe right ventricular dysfunction

          -  Mitral valve anatomy which may preclude proper device treatment

          -  Mitral valve area &lt;4.0 cm2 (if new device therapy may further decrease the mitral
             orifice area)

          -  Any prior mitral valve surgery or transcatheter mitral valve procedure

          -  Stroke or transient ischemic event within 30 days

          -  Modified Rankin Scale ≥ 4 disability

          -  Need for emergent or urgent surgery for any reason or any planned cardiac surgery
             within the next 12 months

          -  Absence of CRT with Class I indication criteria for biventricular pacing

          -  Implant or revision of any rhythm management device (CRT or CRT-D) or implantable
             cardioverter-defibrillator within 1 month

          -  Untreated clinically significant coronary artery disease requiring revascularization

          -  Severe symptomatic carotid stenosis (&gt;70% by ultrasound).

          -  Myocardial infarction ≤ 30 days

          -  Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid
             surgery within 30 days

          -  Tricuspid valve disease requiring surgery or severe tricuspid regurgitation (per ASE
             guidelines; core lab assessment)

          -  Aortic valve disease requiring surgery

          -  Moderate or severe aortic valve stenosis or regurgitation

          -  Aortic valve prosthesis

          -  Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile
             aortic atheroma, intracardiac mass, thrombus, or vegetation

          -  Need for any cardiovascular surgery (other than for MV disease)

          -  Active endocarditis

          -  Anatomical pathology/constraints preventing appropriate access/implant of the
             AccuCinch System (e.g., femoral arteries will not support an 18F system)

          -  Known allergy to nickel, polyester, or polyethylene

          -  Active infections requiring current antibiotic therapy

          -  Currently participating in another interventional investigational study

          -  Subjects in whom transesophageal echocardiography is contraindicated or high risk

          -  Any condition making it unlikely the patient will be able to complete all protocol
             procedures (including compliance with guideline directed medical therapy) and
             follow-up visits

          -  Patient (or legal guardian) unable or unwilling to provide written, informed consent
             before study enrollment

          -  Pregnant or planning pregnancy within next 12 months. Note: Female patients of
             childbearing potential need to have a negative pregnancy test performed within 14 days
             prior to intervention and be adherent to an accepted method of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Zapien, MS, CCRA</last_name>
    <role>Study Director</role>
    <affiliation>Ancora Heart, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Zapien, MS, CCRA</last_name>
    <phone>408-727-1105</phone>
    <phone_ext>204</phone_ext>
    <email>mzapien@ancoraheart.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rossella Mercuri</last_name>
    <email>r.mercuri@meditrial.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Dumonteil</last_name>
      <email>ndumonteil@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Nicolas Dumonteil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Azeem Latib</last_name>
      <email>alatib@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Azeem Latib</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mike Bosschaert</last_name>
      <email>m.bosschaert@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Jan van der Heijden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital, Belfast Trust</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Spence</last_name>
      <email>marks.spence@belfasttrust.hscni.net</email>
    </contact>
    <investigator>
      <last_name>Mark Spence</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brompton &amp; Harefield NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lauren Kelly</last_name>
      <email>l.kelly2@rbht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Rob Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

